“Cobenfy represents the first truly new therapeutic approach for schizophrenia in decades,” noted Gang Wang, MD, dean of Beijing Anding Hospital, Capital Medical University and the leading principal investigator for the Phase 3 China study.1 Wang highlighted that “Cobenfy has demonstrated comprehensive improvement across positive, negative and cognitive symptoms, while avoiding many of the adverse effects commonly associated with traditional antipsychotics, including weight gain, hyperprolactinemia, and a problematic movement disorder called extrapyramidal symptoms, offering a meaningful new option for patients.”
4 Likes